Kidney Cancer Survival Rate
The kidney cancer survival rate is a measurement that some physicians use to discuss and evaluate kidney cancer outcomes. This information is a statistical average only; individual cases vary widely in their results, depending on the characteristics of the cancer and other factors. Some individuals find that learning about statistical information is helpful, while others do not.
Cancer researchers use a five-year survival rate as the standard measurement for establishing a statistical prognosis. This rate represents the percentage of patients who live at least five years after their cancer is diagnosed and staged. Of course, many of these patients live much longer than five years. It should be noted that kidney cancer survival rate statistics do not differentiate between people who died as a direct result of kidney cancer and those who may have died from other causes. Because kidney cancer patients tend to be over 45, other health issues may affect survival rates. Plus, cancer treatments are improving every day, so the treatments received today may be more effective than those received five years ago. There are several factors that can have a positive impact on a patient’s survival rate, including:
- Early intervention
- Comprehensive treatment
- Innovative therapies
At Moffitt Cancer Center, our surgeons, oncologists, researchers and other members of our multispecialty cancer team are committed to continually improving survival rates and patients’ quality of life. Our cancer research spans multiple disciplines in order to provide more comprehensive benefits in cancer patient care. We are tireless in our pursuit of new screening techniques as well, with a goal to diagnose kidney cancer as early as possible – a key factor in improving outcomes. For more information on the survival rate for kidney cancer and the treatment options available through Moffitt’s Urologic Oncology Program, call 1-888-663-3488 or complete our online new patient registration form. No referral is required to meet with our team of oncologists who specialize in kidney cancer.